Orrick, Herrington & Sutcliffe LLP
04/16/2025 | Press release | Distributed by Public on 04/16/2025 08:07
Orrick Advises Ananda Pharma on US OTCQB Listing
Orrick advised Ananda Pharma plc (AQSE: ANA) on the admission to trading of its ordinary shares on the OTCQB Venture Market (OTCQB) in the United States of America (US).
THE COMPANY
Andana Pharma is a United Kingdom-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions.
THE IMPACT
The trading of Andana Pharma's ordinary shares on OTCQB commenced on 14 April 2025 under the ticker "ANANF." There was no capital raise associated with this cross trade and the ordinary shares will continue to trade on Ananda Pharma's primary listing market, the Apex segment of the Aquis Stock Exchange (AQSE) in London.
Cross trading on OTCQB allows Ananda Pharma to access one of the world's largest investment markets to expand its reach into a broader pool of investors and build brand awareness in the most important pharmaceutical market in the world. Andana Pharma's ordinary shares will be available to US investors during US working hours and priced in US Dollars and should lead to easier cross-border trading for potential US investors.